MSH Capital Advisors LLC Takes $418,000 Position in IQVIA Holdings Inc. (NYSE:IQV)

MSH Capital Advisors LLC bought a new position in shares of IQVIA Holdings Inc. (NYSE:IQV) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 2,125 shares of the medical research company’s stock, valued at approximately $418,000.

Other large investors have also recently modified their holdings of the company. Marshall Wace LLP boosted its holdings in IQVIA by 85.4% in the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company’s stock worth $187,528,000 after buying an additional 439,649 shares during the period. NFJ Investment Group LLC boosted its holdings in shares of IQVIA by 20.5% in the fourth quarter. NFJ Investment Group LLC now owns 36,893 shares of the medical research company’s stock worth $7,250,000 after acquiring an additional 6,282 shares during the period. Guggenheim Capital LLC grew its position in shares of IQVIA by 5.3% in the fourth quarter. Guggenheim Capital LLC now owns 22,552 shares of the medical research company’s stock valued at $4,432,000 after purchasing an additional 1,140 shares in the last quarter. Canada Post Corp Registered Pension Plan bought a new stake in shares of IQVIA during the 4th quarter valued at $572,000. Finally, Stamos Capital Partners L.P. bought a new stake in shares of IQVIA during the 4th quarter valued at $1,490,000. Hedge funds and other institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

IQVIA stock opened at $148.73 on Thursday. The firm has a fifty day simple moving average of $178.83 and a two-hundred day simple moving average of $198.11. IQVIA Holdings Inc. has a twelve month low of $135.97 and a twelve month high of $252.88. The company has a market capitalization of $26.22 billion, a PE ratio of 19.83, a P/E/G ratio of 1.99 and a beta of 1.46. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last issued its earnings results on Thursday, February 6th. The medical research company reported $2.90 earnings per share for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a net margin of 8.91% and a return on equity of 28.81%. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on IQV shares. Citigroup reduced their target price on IQVIA from $225.00 to $210.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. UBS Group decreased their target price on shares of IQVIA from $260.00 to $255.00 and set a “buy” rating on the stock in a report on Friday, February 7th. Barclays reissued an “equal weight” rating and issued a $170.00 price target (down from $235.00) on shares of IQVIA in a report on Thursday, April 10th. BTIG Research cut shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Monday, February 3rd. Finally, Truist Financial dropped their price objective on IQVIA from $263.00 to $216.00 and set a “buy” rating for the company in a research note on Thursday, April 10th. Six research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $241.50.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.